NCT06937567View on ClinicalTrials.gov

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions
Biliary Tract CancerColorectal CarcinomaGastric Cancer, MetastaticPancreatic Adenocarcinoma (Ductal Adenocarcinoma)Multiple Cancer
Interventions
BIOLOGICAL

CDH17 CAR-T

The initial dose of cell therapy in this clinical study was set at 1.0×106/Kg and the maximum dose was set at 6.0×106/Kg.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Zhejiang University

OTHER